- Home
- TFX vs PTGX Comparison
TFX vs PTGX Comparison
Compare TFX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TFX | PTGX |
|---|---|---|
| Founded | 1943 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | TFX | PTGX |
|---|---|---|
| Price | $109.97 | $80.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 9 |
| Target Price | ★ $139.88 | $93.00 |
| AVG Volume (30 Days) | 732.0K | ★ 905.5K |
| Earning Date | 02-26-2026 | 02-20-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | ★ $3,189,988,000.00 | $209,217,000.00 |
| Revenue This Year | $9.90 | N/A |
| Revenue Next Year | $10.51 | $288.98 |
| P/E Ratio | ★ N/A | $111.36 |
| Revenue Growth | ★ 5.42 | N/A |
| 52 Week Low | $102.58 | $33.70 |
| 52 Week High | $185.94 | $96.54 |
Technical Indicators
Market Signals| Indicator | TFX | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 33.05 | 34.87 |
| Support Level | $108.39 | $79.18 |
| Resistance Level | $127.49 | $89.61 |
| Average True Range (ATR) | 3.05 | 2.73 |
| MACD | -1.50 | -1.18 |
| Stochastic Oscillator | 10.79 | 14.51 |
Price Performance
Historical ComparisonAbout TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.